Xenon Pharmaceuticals Inc. Quarterly Deferred Income Tax Expense (Benefit) in USD from Q1 2018 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
Xenon Pharmaceuticals Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from Q1 2018 to Q1 2024.
  • Xenon Pharmaceuticals Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was $403K, a 39.9% increase year-over-year.
  • Xenon Pharmaceuticals Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was -$292K, a 564% decline from 2022.
  • Xenon Pharmaceuticals Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was -$44K, a 176% decline from 2021.
  • Xenon Pharmaceuticals Inc. annual Deferred Income Tax Expense (Benefit) for 2021 was $58K.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $403K +$115K +39.9% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q1 2023 $288K +$30K +11.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q1 2022 $258K +$249K +2767% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q1 2021 $9K -$43K -82.7% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q1 2020 $52K +$19K +57.6% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-11
Q1 2019 $33K +$70K Jan 1, 2019 Mar 31, 2019 10-Q/A 2020-05-26
Q1 2018 -$37K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.